Translational Breast Cancer Research : a Journal Focusing on Translational Research in Breast Cancer
Overview
Translational Breast Cancer Research : a Journal Focusing on Translational Research in Breast Cancer is a scientific journal, published by AME Publishing Company since 2020 in English. The journal's country of origin is China.
Details
Details
Abbr.
Transl Breast Cancer Res
Publisher
AME Publishing Company
Start
2020
End
Continuing
Frequency
Quarterly
e-ISSN
2218-6778
Country
China
Language
English
Recent Articles
1.
Rodriguez Y, Koomson A, Perry R
Transl Breast Cancer Res
. 2025 Feb;
6:8.
PMID: 39980815
Background And Objective: Breast, endometrial, and ovarian cancers (OCs) are significant public health concerns. Approximately three million patients are diagnosed with one of the three tumor types annually. The three...
2.
Zurbuchen E, Yu N, Salibian A
Transl Breast Cancer Res
. 2025 Feb;
6:6.
PMID: 39980814
Background And Objective: Lymphedema is a chronic, progressive disease secondary to damage to the lymphatic system that results in interstitial fluid accumulation, fat deposition and inflammation. Lymphatic surgery includes a...
3.
4.
Fancellu A, Giuliani G, Mulas S, Contini A, Ariu M, Sanna V
Transl Breast Cancer Res
. 2025 Feb;
6:5.
PMID: 39980812
Background And Objective: In the era of de-escalation and minimally invasive locoregional treatments across many fields of surgical oncology, the treatment of the axilla in breast cancer has garnered significant...
5.
Takahashi H
Transl Breast Cancer Res
. 2025 Feb;
6:7.
PMID: 39980811
No treatment has been established for meningeal carcinomatosis (MC) in advanced metastatic breast cancer, and its prognosis is poor. In recent years, systemic therapies such as trastuzumab deruxtecan and tucatinib...
6.
7.
8.
Underlying factors that affect ultrasound conspicuity of breast biopsy markers: an exploratory study
Cario J, Lee C, Oelze M
Transl Breast Cancer Res
. 2025 Feb;
6:2.
PMID: 39980808
Background: During management of node-positive breast cancer, neoadjuvant systemic therapy (NST) is often used to de-escalate surgical intervention. To identify pathology-proven positive nodes regardless of visual changes after NST, breast...
9.
Targeting low-risk triple-negative breast cancer: a review on de-escalation strategies for a new era
Carvalho F
Transl Breast Cancer Res
. 2025 Feb;
6:4.
PMID: 39980807
Triple-negative breast cancer (TNBC) is a subtype of breast cancer lacking estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) expression. Comprising 15-20% of breast...
10.
Jiang K, Wang S
Transl Breast Cancer Res
. 2025 Feb;
6:9.
PMID: 39980806
Background And Objective: Triple-negative breast cancer (TNBC) is more aggressive when compared with other breast cancer subtypes, and advanced TNBC (aTNBC) has always been a challenge for clinical treatment. In...